NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 | |
|---|---|---|---|---|---|
| Current Liabilities | - | - | - | - | - |
What is the latest Current Liabilities ratio of NATH BIOGENES (INDIA) ?
| Year | Current Liabilities |
|---|---|
| Mar2025 | - |
| Mar2024 | - |
| Mar2023 | - |
| Mar2022 | - |
| Mar2013 | - |
How is Current Liabilities of NATH BIOGENES (INDIA) Trending?
| Years | Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | - | 0 | |
| Mar2024 | - | 0 | |
| Mar2023 | - | 0 | |
| Mar2022 | - | 0 | |
| Mar2013 | - | - | |
Compare Current Liabilities of peers of NATH BIOGENES (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATH BIOGENES (INDIA) | ₹311.4 Cr | -6.1% | 7.4% | 1.5% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹10,446.6 Cr | -4.2% | 0.6% | -16.1% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹4,854.6 Cr | -6% | 2% | -32.2% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,410.7 Cr | 5.9% | 17.2% | -0.3% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹983.7 Cr | -3.6% | -3.9% | -25.3% | Stock Analytics | |
| INDO US BIOTECH | ₹208.5 Cr | -7.6% | -3% | -24.4% | Stock Analytics | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | -6.1% |
7.4% |
1.5% |
| SENSEX | -4.3% |
-2.6% |
-7.6% |
You may also like the below Video Courses